Edoxaban

Stroke Prevention

Edoxaban is prescribed to reduce the risk of stroke and systemic embolism in adults with nonvalvular atrial fibrillation. This is a condition where the heart beats irregularly, which can cause blood to pool and form clots that may travel to the brain or other parts of the body. It is specifically used for atrial fibrillation that is not caused by a heart valve problem.

Treatment of Blood Clots

This medication is also used to treat and prevent the recurrence of two types of serious blood clots:

• Deep vein thrombosis (DVT): A blood clot that forms in a deep vein, typically in the legs.
• Pulmonary embolism (PE): A blood clot that travels to the lungs and blocks an artery.

When used to treat DVT or PE, edoxaban is typically started only after the patient has received an injectable blood thinner for 5 to 10 days. It helps treat the current clot and lowers the risk of another clot forming in the future.

Mechanism of Action

Edoxaban belongs to a class of medications called factor Xa inhibitors. It works by directly blocking the activity of factor Xa, which is a key enzyme involved in the blood clotting process. Under normal conditions, factor Xa helps the body produce thrombin, a substance that triggers the formation of blood clots.

By inhibiting factor Xa, edoxaban reduces the amount of thrombin produced in the body. This makes the blood less likely to form clots and prevents existing clots from growing larger. Because it targets a specific step in the clotting sequence, it is often referred to as a direct oral anticoagulant (DOAC).

How It Affects the Body

When edoxaban is taken, it enters the bloodstream and begins to interfere with the coagulation cascade. This process is beneficial for individuals at risk of certain medical conditions, such as:

• Stroke prevention: In people with an irregular heartbeat (atrial fibrillation), it helps prevent clots from forming in the heart and traveling to the brain.
• Treating venous thromboembolism: It helps manage clots that form in the deep veins of the legs or travel to the lungs.

Unlike some older blood thinners, edoxaban works directly on the clotting factor without requiring additional proteins to be effective. Its effects generally begin shortly after the medication is absorbed into the system.

Common Side Effects

The most frequently reported side effect of edoxaban is bleeding. Other common side effects may include:

• Anemia (low red blood cell count)
• Skin rash
• Abnormal liver function test results

Serious Side Effects

Edoxaban can cause serious bleeding because it lowers the body's ability to form blood clots. Seek medical attention immediately if you experience any of the following signs of severe bleeding:

• Unexpected bleeding or bleeding that lasts a long time, such as frequent nosebleeds or bleeding gums
• Menstrual bleeding that is much heavier than normal
• Pink, red, or brown urine
• Bright red or black, tarry stools
• Coughing up blood or vomit that looks like coffee grounds
• Severe headache, dizziness, or weakness
• Pain, swelling, or new drainage at wound sites

In rare cases, edoxaban may cause a serious allergic reaction. Symptoms include hives, rash, swelling of the face or throat, and difficulty breathing.

Boxed Warnings

Stopping treatment early: Discontinuing edoxaban before the intended time increases the risk of blood clots and stroke. If the medication must be stopped for reasons other than bleeding, a healthcare provider may prescribe another blood thinner to prevent clots.

Spinal or epidural hematoma: People receiving spinal anesthesia or a spinal puncture while taking edoxaban are at risk of developing a blood clot in the spine (hematoma). This can lead to long-term or permanent paralysis. Risk factors include the use of indwelling epidural catheters or taking other medications that affect blood clotting, such as nonsteroidal anti-inflammatory drugs (NSAIDs).

Reduced effectiveness in certain patients: In people with nonvalvular atrial fibrillation, edoxaban may be less effective at preventing strokes if kidney function is very high (creatinine clearance greater than 95 mL/min). Kidney function is typically assessed before starting treatment.

Bleeding Risks

Edoxaban increases the risk of serious and potentially fatal bleeding because it prevents blood from clotting. This may cause easier bruising or longer bleeding times. Seek immediate medical attention for signs of internal bleeding, such as:

• Red, pink, or brown urine.
• Bright red or black, tarry stools.
• Coughing up blood or vomit that looks like coffee grounds.
• Unusual pain, swelling, or new discomfort.

Other Precautions

Prosthetic heart valves: Edoxaban is not recommended for people with mechanical heart valves or moderate-to-severe mitral stenosis, as its safety and effectiveness have not been established in these groups.

Liver and kidney function: This medication is not recommended for individuals with severe liver disease. Because the drug is cleared by the kidneys, function should be monitored regularly, as dosage adjustments may be required for those with impaired kidney function.

Surgery and procedures: Edoxaban may need to be temporarily stopped before surgical or dental procedures to reduce the risk of bleeding. It should be restarted as soon as a healthcare professional determines it is safe.

Pregnancy

There is limited information regarding the safety of edoxaban use during pregnancy. While animal studies have not demonstrated a direct risk of birth defects, there are no adequate studies in humans to confirm its safety. Using blood thinners during pregnancy can increase the risk of bleeding for both the mother and the fetus.

Individuals who are pregnant or planning to become pregnant should consult with a healthcare professional to evaluate the risks and benefits. People of childbearing potential may be advised to use effective contraception while taking this medication.

Breastfeeding

It is not known if edoxaban passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is generally not recommended during treatment. A decision should be made in consultation with a healthcare provider to either stop breastfeeding or stop taking the medication, based on the clinical necessity of the treatment for the mother.

Edoxaban is available in the following form:

• Oral Tablet: This medication is provided as a film-coated tablet for oral administration.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved edoxaban for the following indications:

• To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
• To treat deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial treatment with an injectable anticoagulant.

Boxed Warnings

Edoxaban carries several boxed warnings, which are the most serious warnings required by the FDA to alert consumers and healthcare providers to significant safety risks:

• Reduced Efficacy in NVAF with High Kidney Function: Edoxaban should not be used in patients with nonvalvular atrial fibrillation who have a creatinine clearance (CrCl) greater than 95 mL/min. Clinical trials indicated that these patients have an increased risk of ischemic stroke compared to those taking warfarin.
• Risk of Stroke After Premature Discontinuation: Stopping edoxaban earlier than directed increases the risk of blood clots and stroke. If the medication must be stopped for reasons other than major bleeding, another anticoagulant should typically be started.
• Spinal/Epidural Hematoma: Patients taking edoxaban who undergo spinal puncture or receive neuraxial anesthesia (such as an epidural) are at risk of developing a blood clot around the spine. These hematomas can cause long-term or permanent paralysis.

International Regulatory Status

Edoxaban is also approved for use in other regions, including the United Kingdom and the European Union, where it is marketed under the brand name Lixiana for the prevention of stroke in atrial fibrillation and the treatment and prevention of DVT and PE.

Factors Affecting Price

Several variables determine the final cost of edoxaban:

• Insurance Plan: Most insurance providers cover edoxaban, but the specific tier and copay amount will vary by plan.
• Pharmacy Location: Retail prices can differ between pharmacies; comparing prices at different locations or using mail-order options may reduce costs.
• Supply Amount: Purchasing a 90-day supply instead of a 30-day supply may sometimes offer a lower cost per dose.

Generic Availability

Edoxaban is sold under the brand name Savaysa. Generic versions are generally more affordable than brand-name drugs. However, the availability of generic edoxaban depends on regional patent laws and regulatory approvals. You should consult your pharmacist to see if a generic alternative is available and covered by your insurance.

Assistance and Savings

Many manufacturers provide financial assistance for brand-name medications. This may include savings cards for those with commercial insurance or patient assistance programs for individuals who meet specific income requirements or lack insurance coverage.